Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein...

Details Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein... Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein...

2005-11-08

2005-11-08

McKenzie, Thomas C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S517000

Reexamination Certificate

active

06962913

ABSTRACT:
This invention relates to novel compounds of the class of succinoyl lactams, such as diazepinee of Formula (Id),or a pharmaceutically acceptable salt thereof, as described above, having drug and bio-affecting properties. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of Alzheimer's disease.

REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4929614 (1990-05-01), Calvet et al.
patent: 5175159 (1992-12-01), Bock et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5532359 (1996-07-01), Marsters et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5545735 (1996-08-01), Bochis et al.
patent: 5550126 (1996-08-01), Horwell et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5578629 (1996-11-01), Ciccarone et al.
patent: 5590851 (1997-01-01), Ackerman
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5594006 (1997-01-01), Sakamoto et al.
patent: 5595990 (1997-01-01), Baldwin et al.
patent: 5602145 (1997-02-01), Samanen
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5618812 (1997-04-01), Pineiro et al.
patent: 5639746 (1997-06-01), Yelm
patent: 5672596 (1997-09-01), Wyvratt et al.
patent: 5672598 (1997-09-01), De et al.
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 5710153 (1998-01-01), Ohmoto et al.
patent: 5710171 (1998-01-01), Dinsmore et al.
patent: 5734054 (1998-03-01), Dolle, III et al.
patent: 5756528 (1998-05-01), Anthony et al.
patent: 5763437 (1998-06-01), Sato et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5840939 (1998-11-01), Beckett et al.
patent: 5852010 (1998-12-01), Graham et al.
patent: 5856326 (1999-01-01), Anthony et al.
patent: 5859012 (1999-01-01), Dinsmore et al.
patent: 5869682 (1999-02-01), DeSolms
patent: 5872135 (1999-02-01), DeSolms
patent: 5874424 (1999-02-01), Batchelor et al.
patent: 5885995 (1999-03-01), Dinsmore
patent: 5891889 (1999-04-01), Anthony et al.
patent: 5905077 (1999-05-01), Jungheim et al.
patent: 5919785 (1999-07-01), Dinsmore et al.
patent: 5936089 (1999-08-01), Carpino et al.
patent: 5965578 (1999-10-01), Graham et al.
patent: 5968924 (1999-10-01), Wyvratt et al.
patent: 5968965 (1999-10-01), Dinsmore et al.
patent: 5985900 (1999-11-01), Abreo et al.
patent: 5998447 (1999-12-01), Stilz et al.
patent: 6001835 (1999-12-01), Dinsmore et al.
patent: 6057660 (2000-05-01), Meier et al.
patent: 6060038 (2000-05-01), Burns et al.
patent: 6066738 (2000-05-01), Dinsmore et al.
patent: 6093737 (2000-07-01), Anthony et al.
patent: 6117910 (2000-09-01), Callahan et al.
patent: 6127427 (2000-10-01), Martin et al.
patent: 6228854 (2001-05-01), Scarborough et al.
patent: 6242455 (2001-06-01), Grams et al.
patent: 6262047 (2001-07-01), Zhu et al.
patent: 6271262 (2001-08-01), Beckett et al.
patent: 6297239 (2001-10-01), DeSolms et al.
patent: 6329373 (2001-12-01), Martin et al.
patent: 6333321 (2001-12-01), Scarborough
patent: 6358987 (2002-03-01), Beckett et al.
patent: 6432947 (2002-08-01), Arnaiz et al.
patent: 6440965 (2002-08-01), Kelley et al.
patent: 0276436 (1987-12-01), None
patent: 0421802 (1991-04-01), None
patent: 0434360 (1991-06-01), None
patent: 0606046 (1993-12-01), None
patent: 0652009 (1995-05-01), None
patent: 0842944 (1998-05-01), None
patent: WO 92/00374 (1992-01-01), None
patent: WO 92/06966 (1992-04-01), None
patent: WO 9217460 (1992-10-01), None
patent: WO 9403437 (1994-02-01), None
patent: WO 9405634 (1994-03-01), None
patent: WO 9414776 (1994-07-01), None
patent: WO 9509633 (1995-04-01), None
patent: WO 95/22966 (1995-08-01), None
patent: WO 9617833 (1996-06-01), None
patent: WO 9618602 (1996-06-01), None
patent: WO 9620918 (1996-07-01), None
patent: WO 9629313 (1996-09-01), None
patent: WO 9633165 (1996-10-01), None
patent: WO 9639137 (1996-12-01), None
patent: WO 9942889 (1997-02-01), None
patent: WO 9712861 (1997-04-01), None
patent: WO 97/18207 (1997-05-01), None
patent: WO 9719053 (1997-05-01), None
patent: WO 9727852 (1997-08-01), None
patent: WO 9736877 (1997-10-01), None
patent: WO 9736879 (1997-10-01), None
patent: WO 9736900 (1997-10-01), None
patent: WO 9738664 (1997-10-01), None
patent: WO 9745412 (1997-12-01), None
patent: WO 98/15828 (1998-04-01), None
patent: WO 9816523 (1998-04-01), None
patent: WO 9822430 (1998-05-01), None
patent: WO 9822433 (1998-05-01), None
patent: WO 9822441 (1998-05-01), None
patent: WO 9822493 (1998-05-01), None
patent: WO 9827053 (1998-06-01), None
patent: WO 9828268 (1998-07-01), None
patent: WO 9828980 (1998-07-01), None
patent: WO 9837079 (1998-08-01), None
patent: WO 9841510 (1998-09-01), None
patent: WO 9844797 (1998-10-01), None
patent: WO 98/51665 (1998-11-01), None
patent: WO 9858915 (1998-12-01), None
patent: WO 9900654 (1999-01-01), None
patent: WO 9903826 (1999-01-01), None
patent: WO 9907730 (1999-02-01), None
patent: WO 9907731 (1999-02-01), None
patent: WO 9917777 (1999-04-01), None
patent: WO 9918951 (1999-04-01), None
patent: WO 9919305 (1999-04-01), None
patent: WO 9932453 (1999-07-01), None
patent: WO 9966934 (1999-12-01), None
patent: WO 9967219 (1999-12-01), None
patent: WO 9967220 (1999-12-01), None
patent: WO 9967221 (1999-12-01), None
patent: WO 0002903 (2000-01-01), None
patent: WO 0007995 (2000-02-01), None
patent: WO 0028331 (2000-05-01), None
patent: WO 0038618 (2000-07-01), None
patent: WO 0160826 (2001-08-01), None
James C Anthony; John CS Breitner; Peter P Zandi, Expert Opinion on Pharmacotherapy, 2002, vol. 3, No. 4, pp. 365-380.
AJ Larner, Expert Opinion on Therapeutic Patents, 2004, vol. 14, No. 10, pp. 1403-1420.
Kornilova, Anna Y et al, Ann. Reports Med. Chem., vol. 41, 2003, pp. 41-50.
Olson, R.E. et al, “Annual Rports Med. Chem.”, 35, 2000, 31-40.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Achour et al.,Synth. Commun. 1994, 24 (20), pp. 2899-2905.
A. Ahmed et al.,FEBS Letters, (1984), vol. 174, pp. 76-79.
P. Becket, M. J. Crimmin, M. H. Davis, and Z. Spavold,Synlett(1993), pp. 137-138.
Bioorg. Med. Chem. Lett., vol. 8, No. 16, pp. 2077-2080.
Bock et al.,J. Med. Chem. 1993, 36, pp. 4276-4292.
Bock et al.,J. Org. Chem 1987, 52, pp. 3232-3239.
Bodine et al.,Synth. Commun. 1982, 12, p. 787.
Buege et al.,Arch. Pharm. 1994, 327 (2), pp. 99-103.
F. A. Carey and R. J. Sundberg, “Advanced Organic Chemistry, Part A,”New York: Plenum Press, 1990, pp. 304-305, 342-347, 475-479, 695-698.
Duhammel et al.,Tetrahedron Asymmetry 1991,2(3),pp. 203-206.
D. A. Evans et al.,Org. Synth 1990, 68, pp. 83-91.
Glenner and Wong,Biochem. Biophys. Res. Commun., 120: pp. 885-890.
J. Higaki, D. Quon, Z. Zhong, B. Cordell, “Inhibition of beta-amyloid Formation identifies Proteolytic Precursors and Subcellular Site of Catabolism”,Neuron 14, pp. 651-659, 1995.
Jacobson and Reddy, Tetrahedron Letters, vol. 37, No. 46, pp. 8263-8266 (1996).
McClure and Axt,Bioorganic & Medicinal Chemistry Letters, 8 (1998), pp. 143-146.
M. G. Natchus et al., “Design and synthesis of conformationally constrained MMP inhibitors,” Chemical Abstracts, vol. 129, No. 22, Nov. 30, 1998, abstract No. 290051p.
C. F. Nutaitis and M. W. Ledeboer,Org.Prep. Proced. Int.(1992), 24(2), pp. 143-146.
Pratt et al.,Synlett, May 1998, p. 531.
“Remington's Pharmaceutical Sciences,” 17thed. Mack Publishing Company, Easton, PA, 1985, p. 1418.
D. J. Selkoe, “Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease,”Annu. Rev. Cell. Biol., 1994, 10: pp 373-403.
Schwartz et al.,Tetrahedron, 1997, 53 (26), pp. 8795-8806.
Sherrill and Sugg,J. Org. Chem. 1995, 60, pp. 730-734.
Taylor et al.,Bioorg. Med. Chem. Lett. 1997, 7 (4), pp. 453-456.
D. A. Walsh,Synthesis, Sep.

Affiliated with

Also associated with

Rating

Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3460468